This trial is testing the safety of Anti-SLAMF7 CAR-T cells in myeloma. The Anti-SLAMF7 CAR-T cells in this trial are altered to include a ‘stop switch’, to help limit toxicity of this therapy.
SparkCures ID | 1004 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 42 Patients |
Treatments | |
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
INCLUSION CRITERIA - OTHER:
EXCLUSION CRITERIA:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersRead the latest news and updates on this trial.
December 05, 2019
Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies.
SparkCures is working closely with National Cancer Institute (NCI) to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors